MedTrace Logo

Metabolomics Explores Biomarkers for Metastatic Breast Cancer

NCT04302415 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2020-03-10

No results posted yet for this study

Summary

RATIONALE: Studying samples of plasm by metabolomics-based approach from women with metastasis breast cancer may help doctors understand the biomarker of visceral metastasis.

PURPOSE: This clinical trial is studying the biomarker of visceral metastasis by metabolomics approach in metastasis breast cancer undergoing treatment.

Conditions

Interventions

DRUG

There is no other intervention, only clinical treatment.

There is no other intervention, only clinical treatment.

Sponsors & Collaborators

  • Shandong Cancer Hospital and Institute

    lead OTHER

Principal Investigators

  • YU Zhiyong, PhD · Shandong Cancer Hospital and Institute

  • WANG Fukai, MM · Shandong Cancer Hospital and Institute

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2020-03-01
Completion
2023-02-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04302415 on ClinicalTrials.gov